The clinical pilot study of MediRätt's digital drug dispensing machine Dosell is now successfully completed. The study confirms the weaknesses of Dosett and Apodos dispensing aids and shows positive results for Dosell.
The study has compared the storage container Dosett with the dose bags Apodos as well as evaluated how MediRätt's digital drug dispenser Dosell works in practice. The result of the study confirms the risk of various types of mismedication with Dosett and Apodos. The study also confirms other shortcomings of existing home dispensing aids - the Dosett cassettes proved to be difficult and time consuming for district nurses to handle, among other things.
The drug dispenser Dosell worked flawlessly in 98.5% of cases. The error is attributable to the hardware and will be addressed in the production of Dosell. The alarm function worked flawlessly in all tests.
"The results of the study confirm our belief that Dosell can both reduce patient suffering and relieve healthcare. Based on the results of the study, it takes a full-time district to charge and load Dosettes at a medium-sized Swedish healthcare center with home care services. Here's a huge potential for Dosell to become a tool that frees resources in healthcare," says Göran Sjönell, general practitioner and inventor of Dosell.
"This is a big breakthrough for us. We have focused intently on developing Dosell for a long time and it is incredibly exciting that the study now shows such a positive result. We are moving forward according to plan and look forward to strengthening our funding without having to raise new capital from existing shareholders in the future, "says Carl Johan Merner, CEO of MediRätt.
The report from the study is posted on the company's website www.mediratt.com and published in Bonnier's newsletter, Läkemedelsmarknaden idag.
Please contact CEO Carl Johan Merner
This information is disclosed by MediRätt AB under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on December 5, 2017 at 08:30 CET.
The trial in brief
The clinical study has been conducted in collaboration with Apoteket. The trial has been led by four doctors and six district nurses responsible for patients in home care. The study has been conducted at two health centers in Stockholm. The variables studied are time consumed in handling the different systems, compliance with the ordination, error doses, Dosell's functionality and alarm, and the satisfaction of patients, relatives and healthcare professionals. For Dosett and Apodos, fifteen patients were included in each test group. Five Dosell prototypes were included in the study, and a total of 325 dose dispensations were performed with Dosell.
MediRätt in brief
In Sweden 5 people die and another 300 are hospitalized due to improper medication. MediRätt is a Swedish medical technology company that develops digital solutions for safer medication and drug dispensing. The company was founded in 2008 by general physician Göran Sjönell and industrialist Sten Röing. MediRätt has developed the patented digital drug dispensing machine Dosell, as well as a series of applications that together form a unique overall concept to ensure that elderly and multi-medicating patients receive reliable and safe medication.
The company is listed on NASDAQ First North since 2016. Erik Penser Bank, 08-463 80 00, is the company's Certified Adviser. Further information is available at www.mediratt.com.
MediRätt AB (publ)
181 33 Lidingö
Tel + 46 (0)8 765 66 33
On November 9, 2018, MediRätt announced that the company had called upon a second tranche of convertibles under the agreement on financing through issuance of convertibles entered into with European Select Growth Opportunities Fund (the "Investor"). MediRätt also informed that the company had decided to, at no consideration, issue 430,851 warrants TO6 to the Investor and 426,692 warrants to iZafe AB (formerly Sensec Personlig Säkerhet AB, currently under name change) with the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt pro rata in proportion to the number of shares in MediRätt they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office.
The shareholders of MediRätt AB, 556762-3391, (the "Company") are hereby invited to an Extraordinary General Meeting on Tuesday, 18 December 2018 at 14.00, at Priority, Skeppsbron 24, Stockholm, Sweden.
On May 21, 2018, MediRätt and European Select Growth Opportunities Fund (the "Investor") signed an agreement under which MediRätt may issue convertible bonds in several tranches for a total maximum amount of SEK 50 million over 18 months. A first tranche of SEK 2.5 million has been issued on June 13, under which all the convertibles have been converted into shares as of today, strengthening the company's equity.
Today, MediRätt's subsidiary signed an agreement with Borlänge municipality after winning a direct procurement for courses in security training. Under the agreement, Sensec will train Borlänge municipality staff on 10 to 15 occasions in three different areas: threats and violence in the workplace, ongoing deadly violence, and emergency preparedness.
In conjunction with MediRätt's Q3 report, Erik Penser Bank today published a follow-up analysis of the company. Against a background of higher than expected sales for Q3, the bank has revised upwards its EBIT estimate by SEK 1.8 million for 2018.
THIRD QUARTER IN BRIEF
2,704 SEK 000s (0 SEK 000s)
PROFIT AFTER TAX:
-2,101 SEK 000s (-1,100 SEK 000s)
PROFIT PER SHARE BEFORE DILLUTION:
-0.2 SEK (-0.1 SEK)
NUMBER OF SHARES AS AT 30 JUNE:
Today, MediRätt has signed a pilot project agreement for Dosell with Uppsala municipality. The trial will be conducted for a period of six months with the option of an extension. If the test is successful, Uppsala municipality may decide to purchase Dosell through a public procurement process.
The process to obtain CE marking for Dosell as a MDD Class 1 medtech product continues as planned. MediRätt is expecting that the process can be completed during week 48.
Yesterday, Erik Penser Bank published an analysis of MediRätt. The share was valued at approximately SEK 22 according to the bank's "base" scenario, which indicates high potential at high risk, according to the bank.
In the summer, MediRätt began a co-operation with Erik Penser Bank regarding independent analysis reports on the company. Following delays, the first analysis is expected to be published next week.
Pressmeddelanden och rapporter via E-post.